Cardiovascular effects of GLP-1 receptor agonism

Winquist, Raymond J.; Gribkoff, Valentin K.

doi:10.1016/bs.apha.2022.02.005

Cited by 6 publications

(1 citation statement)

References 160 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…3,4 The available evidence demonstrates the significance of GLP-1 receptor agonists in the treatment of obesity and the reduction of cardiovascular risk in patients with type 2 diabetes mellitus. 5,6 The cardiovascular benefits provided by GLP-1RAs are found to be significant, independent of its effects on glycemic control. 7 However, the specific mechanisms underlying the cardiovascular protection provided by have not yet been fully elucidated.…”

Section: Introductionmentioning

confidence: 99%

Glucagon-like peptide-1 receptor agonists modestly reduced blood pressure among patients with and without diabetes mellitus: A meta-analysis and meta-regression

Rivera,

Lumbang,

Gaid

et al. 2024

Preprint

View full text Add to dashboard Cite

BackgroundThe cardiovascular benefits provided by glucagon-like peptide-1 receptor agonists (GLP-1RAs) extend beyond weight reduction and glycemic control. One possible mechanism may relate to blood pressure (BP) reduction. We aim to quantify the BP lowering effect by GLP1-RAs.MethodsA comprehensive database search for placebo-controlled randomized controlled trials (RCTs) on GLP-1RA treatment was conducted until December 2023. Data extraction and quality assessment were carried out, employing a robust statistical analysis using a random effects model to determine outcomes with mean difference (MD) in millimeters mercury (mmHg) and 95% confidence intervals (CIs). The primary endpoint was the mean difference in systolic and diastolic BP. Subgroup analyses and meta-regression were done to account for covariates.ResultsCompared to placebo, GLP-1RAs modestly reduced SBP (semaglutide: MD −3.40, [95% CI −4.22 to −2.59, p<0.001], liraglutide: MD −2.61, [95% CI −3.48 to −1.74, p<0.001], dulaglutide: MD −1.46, [95% CI −2.20 to −0.72, p<0.001] and exenatide: MD −3.36, [95% CI - 3.63 to −3.10, p<0.001]). This benefit consistently increased with longer treatment duration. Established people with type 2 diabetes experienced less SBP lowering with semaglutide. DBP reduction was only significant in the exenatide group (MD −0.94, [95% CI −1.78 to −0.1], p=0.03). Among semaglutide cohorts, mean change in hemoglobin A1c and mean change in body mass index were directly associated with SBP reduction.ConclusionPatients on GLP-1RA experienced modest SBP lowering compared to placebo. Only exenatide reduced DBP. Further studies are needed to clarify the mechanisms and the clinical benefit of GLP-1RA effects in BP reduction.

show abstract